Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Vistagen Therapeutics (VTGN) Interest & Investment Income (2023 - 2025)

Vistagen Therapeutics' Interest & Investment Income history spans 3 years, with the latest figure at $648000.0 for Q4 2025.

  • For Q4 2025, Interest & Investment Income fell 37.15% year-over-year to $648000.0; the TTM value through Dec 2025 reached $2.8 million, down 45.61%, while the annual FY2025 figure was $4.6 million, 35.99% up from the prior year.
  • Interest & Investment Income for Q4 2025 was $648000.0 at Vistagen Therapeutics, up from $630000.0 in the prior quarter.
  • Across five years, Interest & Investment Income topped out at $1.5 million in Q4 2023 and bottomed at $98000.0 in Q2 2023.
  • The 3-year median for Interest & Investment Income is $855000.0 (2025), against an average of $899727.3.
  • The largest annual shift saw Interest & Investment Income surged 1326.53% in 2024 before it tumbled 50.51% in 2025.
  • A 3-year view of Interest & Investment Income shows it stood at $1.5 million in 2023, then tumbled by 32.79% to $1.0 million in 2024, then crashed by 37.15% to $648000.0 in 2025.
  • Per Business Quant, the three most recent readings for VTGN's Interest & Investment Income are $648000.0 (Q4 2025), $630000.0 (Q3 2025), and $711000.0 (Q2 2025).